LEARN MORE

Empowering Better Life

Empowering Better Life - Established in 2014, Angsana Molecular & Diagnostics Laboratory Pte Ltd is a company specialising in developing premium genomic assays in three areas that have the largest impact on the Asian population.

Our Services

We specialize in premium genomic assays in 2 main areas, customized to fit the Asian profile

Molecular Oncology

Offer a range of genomics tests in order to gain personalized molecular insights and assist in cancer diagnosis, treatment, and prevention.

LEARN MORE

Why Choose Us

It is our promise towards partnering doctors and patients, to make better informed healthcare decisions for better health outcomes.

Quality Assurance

With CAP accreditation for laboratory facilities, we will ensure the highest standards of service.

Actionable insights

Experience precision healthcare through actionable insights in oncology, allergy testing, and fetomaternal health, tailored to your unique needs.

Affordable and Fast Turnaround time

Our diverse team delivers cost-effective services and the swift delivery of crucial genetic insights without compromising quality.

Premium Services

Discover our premium services, blending cutting-edge genomic technologies with validated assays for unmatched accuracy and speed.

Our Achievements

We specialize in premium genomic assays in 3 main areas, customized to fit the Asian profile

2015

Achieved CAP Accreditation

  • Laboratory set up and obtained MOH license
  • Achieved accreditation by College of American Pathologist (CAP)
  • Developed 10 oncology assays
  • Acquired Allergy Laboratory Pte Ltd and started allergy testing services

2016

Forging new partnerships and expansion

  • Launched new assays
  • [Expanded business to Hong Kong]
  • Signed partnership MOU with ThermoFisher
  • Filed IP patent for Angsana exclusive panel
  • Launched allergy tests on Euroimmun
  • Expanded test menu to include LDT, TT and send-out-tests

2017

Further expansion of tests

  • Signed partnership with Ignyta, Inc. to be the partner molecular test laboratory for STARTRK-2 clinical trial sites in Asia
  • Launch of Pharmacogenetics 50 Genes Panel 
  • Launch of BRCA 1/2 Panel, complete Thyroid/ Lung Cancer Panel, Pan-Haematology/ Lymphoma
  • Launch of family prep screen
  • Signed exclusive distributorship with Counsyl and Admera

2018

Strategic Growth

  • Acquisition by IHH Healthcare of 55% stake
  • Signed exclusive distributorship for Amera PGX50, Agendia Mammaprint / Blueprint

2019

Expansion In Oncology and Allergy Testing

  • Implementation of Biomarker Testing by Biocartis Idylla
  • Expanded allergy tests on Phadia platform

2021

  • PIK3CA genotyping sponsored by Novartis
  • Implementation of Ion Torrent Genexus turn-key Integrated Sequencer for NGS
  • Validation of GeneFusions biomarkers by Biocartis™ Idylla 
  • Expansion of fetal maternal testing services by Natera and iGene

2022

  • Implementation of GeneFusions biomarking testing by Biocartis™ Idylla 
  • Introduction of new Idylla lung panel biomarker screening test 
  • Launched Ion Torrent Genexus turn-key Integrated Sequencer for NGS

2024

Established as an independent laboratory

  • Separated from Parkway Laboratories and established as an independent laboratory
  • Established new 5,000 sq ft laboratory at Starhub Green, Singapore